Skip to content

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
CG Oncology logo
CG OncologyCGON
$5.69B+212%
Arvinas logo
ArvinasARVN
$599.29M+45.3%
Replimune Group logo
Replimune GroupREPL
$717.02M-14.3%
Immunome logo
ImmunomeIMNM
$1.9B+470%

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s enterprise value?
Relmada Therapeutics, Inc. (RLMD) reported enterprise value of $163.63M in Q2 2023.
How has Relmada Therapeutics, Inc.'s enterprise value changed year-over-year?
Relmada Therapeutics, Inc.'s enterprise value decreased by 76.9% year-over-year, from $706.96M to $163.63M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.